Overview

Luminaria harnesses multimodal data in human oncology to power an AI-driven platform that decodes therapeutic resistance, accelerates clinical trials, and transforms target discovery. Founded by leading oncologists, data scientists, and biotech executives, Luminaria integrates pathology, radiology, clinical, and genomic data to reveal the hidden biology of tumors. The platform predicts patient responses to antibody-drug conjugates (ADCs), enabling more efficient trials and uncovering novel resistance mechanisms that drive today’s low response rates. By turning these insights into actionable biology, Luminaria identifies new therapeutic targets to fuel the next generation of treatments.